JP2011519367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519367A5 JP2011519367A5 JP2011506768A JP2011506768A JP2011519367A5 JP 2011519367 A5 JP2011519367 A5 JP 2011519367A5 JP 2011506768 A JP2011506768 A JP 2011506768A JP 2011506768 A JP2011506768 A JP 2011506768A JP 2011519367 A5 JP2011519367 A5 JP 2011519367A5
- Authority
- JP
- Japan
- Prior art keywords
- contrast agent
- individual
- detectable label
- treatment
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002872 contrast media Chemical group 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 230000030833 cell death Effects 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000003137 synaptotagmin Human genes 0.000 claims 4
- 108060008004 synaptotagmin Proteins 0.000 claims 4
- 238000003384 imaging method Methods 0.000 claims 3
- 150000002500 ions Chemical class 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 2
- 229910021645 metal ion Inorganic materials 0.000 claims 2
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 claims 1
- RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000007505 plaque formation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0807831.3A GB0807831D0 (en) | 2008-04-29 | 2008-04-29 | Agents for imaging cell death |
| GB0807831.3 | 2008-04-29 | ||
| PCT/GB2009/001082 WO2009133362A2 (en) | 2008-04-29 | 2009-04-29 | Agents for detecting and imaging cell death |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011519367A JP2011519367A (ja) | 2011-07-07 |
| JP2011519367A5 true JP2011519367A5 (enExample) | 2012-06-07 |
| JP5539324B2 JP5539324B2 (ja) | 2014-07-02 |
Family
ID=39522785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011506768A Expired - Fee Related JP5539324B2 (ja) | 2008-04-29 | 2009-04-29 | 細胞死を検出しイメージングするための薬剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8685371B2 (enExample) |
| EP (1) | EP2280735B1 (enExample) |
| JP (1) | JP5539324B2 (enExample) |
| CA (1) | CA2722914A1 (enExample) |
| GB (1) | GB0807831D0 (enExample) |
| WO (1) | WO2009133362A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5858932B2 (ja) | 2010-02-04 | 2016-02-10 | モルフォテック， インコーポレイテッド | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
| ES2601182T3 (es) * | 2010-05-11 | 2017-02-14 | Fred Hutchinson Cancer Research Center | Variantes de clorotoxina, conjugados y métodos para su utilización |
| EP2575897A4 (en) * | 2010-06-01 | 2016-06-01 | Advanced Proteome Therapeutics Inc | CROSSLINKING OF PROTEINS AND OTHER ENTITIES THROUGH ALPHA-HALO-ACETOPHENONES CONJUGATES, BENZYL HALIDES, QUINONES |
| SG11201504600UA (en) | 2012-12-10 | 2015-07-30 | Hutchinson Fred Cancer Res | Methods for screening |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| US12048732B2 (en) | 2016-04-15 | 2024-07-30 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
| JP2020518240A (ja) * | 2017-01-17 | 2020-06-25 | ザ テキサス エー アンド エム ユニバーシティー システム | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート |
| JP7076016B2 (ja) * | 2018-07-12 | 2022-05-26 | ベックマン コールター， インコーポレイテッド | 固定可能な生存率解析用色素およびその使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040022731A1 (en) | 2002-04-26 | 2004-02-05 | Alexei Bogdanov | In vivo imaging of apoptosis |
| WO2006055855A2 (en) | 2004-11-19 | 2006-05-26 | Mcw Research Foundation, Inc. | Method of imaging cell death in vivo |
| US8506928B2 (en) * | 2007-09-07 | 2013-08-13 | The Regents Of The University Of California | Methods and compounds for targeting tissues |
-
2008
- 2008-04-29 GB GBGB0807831.3A patent/GB0807831D0/en not_active Ceased
-
2009
- 2009-04-29 CA CA2722914A patent/CA2722914A1/en not_active Abandoned
- 2009-04-29 JP JP2011506768A patent/JP5539324B2/ja not_active Expired - Fee Related
- 2009-04-29 US US12/989,310 patent/US8685371B2/en not_active Expired - Fee Related
- 2009-04-29 EP EP09738392.1A patent/EP2280735B1/en active Active
- 2009-04-29 WO PCT/GB2009/001082 patent/WO2009133362A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250230135A1 (en) | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy | |
| Kiess et al. | Prostate-specific membrane antigen as a target for cancer imaging and therapy | |
| KR20200009091A (ko) | 신규 psma-결합제 및 이의 용도 | |
| Chen et al. | Recent progress in the development of metal complexes as β-amyloid imaging probes in the brain | |
| Jalilian | An overview on Ga-68 radiopharmaceuticals for positron emission tomography applications | |
| AU2023347470A1 (en) | High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | |
| Kumar et al. | Potential use of 68Ga-apo-transferrin as a PET imaging agent for detecting Staphylococcus aureus infection | |
| CN110139677A (zh) | 用于放射治疗和诊断成像的制剂 | |
| JP2022532187A (ja) | 腎保護物質としてのパラアミノ馬尿酸（ｐａｈ） | |
| Zhang et al. | Recent progress in therapeutic and diagnostic applications of lanthanides | |
| Alberto | Application of technetium and rhenium in nuclear medicine | |
| CN106975086B (zh) | 一种磁共振/核医学双模态分子影像探针及其制备方法 | |
| JP2016020316A (ja) | Ｐｅｔ用ホウ素化合物 | |
| US20150174273A1 (en) | Imaging and therapeutic methods for treating parathyroid tumors | |
| US20240139351A1 (en) | Targeting system with improved uptake | |
| Prasanphanich et al. | The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals | |
| Fu et al. | In vivo bio-distribution of intravenously injected Tc-99 m labeled ferrite nanoparticles bounded with biocompatible medicals | |
| Wang et al. | Study of magnetic ferrite nanoparticles labeled with 99m Tc-pertechnetate | |
| Young | Imaging and therapeutic radiotracers for prostate cancer | |
| Ahn et al. | Radiometals for Positron Emission Tomography (PET) Imaging | |
| Liu et al. | Biological evaluation of [99mTc] Tc-labeled Buthus martensii Karsch Chlorotoxin peptide for glioma imaging | |
| Molea et al. | Biodistribution pharmacokinetics and dosimetry of 99m Tc-d-glucaric acid in humans | |
| Holm-Jørgensen | Adamanzanes as Bifunctional 64Cu2+ Chelators for Radio-Visualisation and Therapy: Chelation and Transchelation | |
| Moon | Development of a novel iron oxide encapsulated prostate-specific membrane antigen (PSMA) targeting nanoparticle as a dual-modality imaging probe for PET and MRI | |
| Yang et al. | The preparation of 99mTc-DTPA-LSA and its instant lyophilized kit for hepatic receptor imaging |